ADC Therapeutics vs Zymeworks
ADCT and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADCT and ZYME compare
Zymeworks is the larger company, worth 10 times as much as ADC Therapeutics ($2.1B against $204M).
Zymeworks grew revenue faster over the last twelve months (97.8% versus 12.8% for ADC Therapeutics).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with −95.7% at ADC Therapeutics.
Zymeworks scores higher on the StockData Score (10 against 4 for ADC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADCT | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $204M | $2.1B |
| Share price | $1.60 | $29.07 |
| Change, 1 year | −62.0% | 61.1% |
| Change, 5 years | −93.0% | 46.7% |
| Beta (5Y) | 1.99 | 0.84 |
| Employees | 188 | 264 |
| StockData Score | ||
| Total score | 4 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 55.9× |
| P/S | 2.4× (better) | 7.8× |
| P/B | – | 8.0× |
| EV/EBITDA | – | 44.4× |
| FCF yield | −49.2% | −5.5% (better) |
| Fair value | – | $12.06 |
| Margin of safety | – | −141% |
| Growth | ||
| Revenue growth (TTM) | 12.8% | 97.8% (better) |
| Revenue growth, 5Y average | – | 22.2% |
| Profitability | ||
| Operating margin | −97.7% | 16.6% (better) |
| Net margin | −95.7% | 16.3% (better) |
| FCF margin | −118% | −42.4% (better) |
| Return on equity | – | 15.0% |
| Return on invested capital | – | 21.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1.6× | – |
| Current ratio | 3.05 | 3.30 (better) |
| Altman Z-score | −9.10 | 0.87 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Buyback yield | −20.9% | 8.0% (better) |
| Shareholder yield | −20.9% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 72.9% | 98.1% |
| Held by insiders | 42.8% | 58.9% |
| Insider net buying, 12 months | −$19.6M | −$5.0M (better) |
| Short interest, % of float | 8.8% | 20.3% |
Go deeper
- ADCT stock overview
- ADCT income statement
- ADCT valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.